Novartis Pharmaceuticals

Quick facts

Marketed products

• Zolgensma · Other · revenue 925
• Aliskiren 150 mg
• Anti Thymocyte Globulin
• Avelox · Infectious Disease
• Beovu · Metabolic
• Certican®
• Chelation · Other
• Coartem · Other
• Desferasirox · Other
• Disease Modifying therapy
• EC-MPS, Tacrolimus
• Entresto · Other
  ENTRESTO inhibits neprilysin to increase natriuretic peptides while blocking AT1 angiotensin II receptors to reduce angiotensin II effects in heart failure.
• Fingolimod 0.5mg
• Fluticasone propionate 100 mcg
• Fluticasone propionate 500 mcg
• FTY720 · Immunology
• iDMT
• inclisiran sodium injection
• interferon or glatiramer acetate
• LABA
• Myfortic · Other
• Neoral · Immunology
• NVA237
• Ofatunumab · Other
• Onasemnogene Abeparvovec-brve · Neuroscience
  ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons.
• Other treatment · Other
• Protaphane · Other
• ranibizumab 0.5 mg
• Ranibizumab Intravitreal injections
• theophylline based treatment
• Tobramycin inhalation powder
• Valturna · Other
• Zoledronic acid 5mg
• Zoledronic acid in combination with therapy

Phase 3 pipeline

• Adjuvant endocrine therapy
• Ansastrozole · Other
• Depigoid · Other

Phase 2 pipeline

• Crizanlizuamb · Other
• FDC therapy
• Glycopyrronium bromide 12.5ug
• Ribiciclib · Other
• Rozuvastatin · Other
• Secukinmab · Other
• Trametininb · Other
• Treosulfane · Other

Phase 1 pipeline

• 111In-ETN029
• [177Lu]Lu-DOTA-TATE
• 225Ac-PSMA-R2
• BION-1301 Single Dose
• EDK060, dose C
• Everolmus · Other
• FIA586
• GnRH antagonists
• HRO761
• LFX453 H2
• LGT209 300 mg
• LGT209 50 mg
• MHU650
• NJH395
• PKC412
• QAW39A
• triopifexor · Other
• Wafarin · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Novartis Pharmaceuticals portfolio CI brief
• Novartis Pharmaceuticals pipeline updates RSS